Henrik Wiggers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7062754/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Remodeling after myocardial infarction and effects of heart failure treatment investigated by hyperpolarized [1―13 C]pyruvate magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 2022, 87, 57-69.	3.0	0
2	Myocardial efficiency in patients with different aetiologies and stages of heart failure. European Heart Journal Cardiovascular Imaging, 2022, 23, 328-337.	1.2	8
3	Patient-reported outcomes and medication adherence in patients with heart failure. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 287-295.	3.0	26
4	Prognostic impact of self-reported health on clinical outcomes in patients with heart failure. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 397-406.	4.0	6
5	Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. Cardiovascular Drugs and Therapy, 2021, 35, 491-503.	2.6	6
6	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). American Heart Journal, 2021, 231, 137-146.	2.7	21
7	Mitral valvulitis as a severe extra-articular manifestation of rheumatoid arthritis: a case report. European Heart Journal - Case Reports, 2021, 5, ytaa467.	0.6	Ο
8	SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Diabetes, 2021, 70, 800-808.	0.6	32
9	Advance care planning and place of death, hospitalisation and actual place of death in lung, heart and cancer disease: a randomised controlled trial. BMJ Supportive and Palliative Care, 2020, 10, e37-e37.	1.6	20
10	Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 2020, 109, 638-645.	3.3	12
11	A randomised, doubleâ€blind, placeboâ€controlled trial of metformin on myocardial efficiency in insulinâ€resistant chronic heart failure patients without diabetes. European Journal of Heart Failure, 2020, 22, 1628-1637.	7.1	39
12	Advance care planning and longer survival in the terminally ill: a randomised controlled trial unexpected finding. BMJ Supportive and Palliative Care, 2020, 10, 221-222.	1.6	8
13	Predictors of patient-reported outcomes at discharge in patients with heart failure. European Journal of Cardiovascular Nursing, 2020, 19, 748-756.	0.9	5
14	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
15	Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis. International Journal of Infectious Diseases, 2020, 96, 73-81.	3.3	10
16	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
17	Myocardial strain assessed by feature tracking cardiac magnetic resonance in patients with a variety of cardiovascular diseases – A comparison with echocardiography. Scientific Reports, 2019, 9, 11296.	3.3	44
18	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. JACC: Heart Failure, 2019, 7. 717-724.	4.1	29

HENRIK WIGGERS

#	Article	IF	CITATIONS
19	Insulin treatment in heart failure patients: the good, the bad or the ugly?. European Journal of Heart Failure, 2019, 21, 985-987.	7.1	0
20	Advance care planning for patients with lung, heart and cancer diseases and their relatives. International Journal of Palliative Nursing, 2019, 25, 112-127.	0.5	12
21	Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 2019, 139, 2129-2141.	1.6	289
22	Quantitative estimation of extravascular lung water volume and preload by dynamic 15O-water positron emission tomography. European Heart Journal Cardiovascular Imaging, 2019, 20, 1120-1128.	1.2	9
23	Hyperpolarized [1―13 C]pyruvate MRI can image the metabolic shift in cardiac metabolism between the fasted and fed state in a porcine model. Magnetic Resonance in Medicine, 2019, 81, 2655-2665.	3.0	9
24	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18
25	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
26	Heart Failure. Endocrinology and Metabolism Clinics of North America, 2018, 47, 117-135.	3.2	17
27	Acute hypertensive stress imaged by cardiac hyperpolarized [1―13 C]pyruvate magnetic resonance. Magnetic Resonance in Medicine, 2018, 80, 2053-2061.	3.0	9
28	Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. Journal of Nuclear Cardiology, 2018, 25, 169-176.	2.1	32
29	Myocardial Oxygen Consumption and Efficiency in Patients WithÂCardiac Amyloidosis. Journal of the American Heart Association, 2018, 7, e009974.	3.7	24
30	Automatic calculation of myocardial external efficiency using a single 11C-acetate PET scan. Journal of Nuclear Cardiology, 2018, 25, 1937-1944.	2.1	25
31	Test–retest repeatability of myocardial oxidative metabolism and efficiency using standalone dynamic 11C-acetate PET and multimodality approaches in healthy controls. Journal of Nuclear Cardiology, 2018, 25, 1929-1936.	2.1	15
32	Left Ventricular Myocardial Contractile Reserve during Exercise Stress in Healthy Adults: A Two-Dimensional Speckle-Tracking Echocardiographic Study. Journal of the American Society of Echocardiography, 2018, 31, 1116-1126.e1.	2.8	30
33	Myocardial Oxygen Consumption and Efficiency in Aortic Valve Stenosis Patients With and Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	24
34	Ketone Body Infusion With 3â€Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. Journal of the American Heart Association, 2017, 6, .	3.7	144
35	Preferred Place of Care and Death in Terminally Ill Patients with Lung and Heart Disease Compared to Cancer Patients. Journal of Palliative Medicine, 2017, 20, 1217-1224.	1.1	54
36	Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	32

HENRIK WIGGERS

#	Article	IF	CITATIONS
37	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)—a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
38	Penicillin G Treatment in Infective Endocarditis Patients – Does Standard Dosing Result in Therapeutic Plasma Concentrations?. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 179-186.	2.5	5
39	Sub-acute transcatheter aortic valve implantation as bridge to recovery from cardio-pulmonary support following ST-elevation myocardial infarction and cardiogenic shock. International Journal of Cardiology, 2016, 207, 211-212.	1.7	0
40	Infective endocarditis in patients receiving chronic hemodialysis: A 21-year observational cohort study in Denmark. American Heart Journal, 2016, 182, 36-43.	2.7	23
41	Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Research and Care, 2016, 4, e000202.	2.8	13
42	Evaluation of ECC-gated [11C]acetate PET for measuring left ventricular volumes, mass, and myocardial external efficiency. Journal of Nuclear Cardiology, 2016, 23, 670-679.	2.1	17
43	Automatic Extraction of Myocardial Mass and Volume Using Parametric Images from Dynamic Nongated PET. Journal of Nuclear Medicine, 2016, 57, 1382-1387.	5.0	14
44	A systematic review of biomarkers in the diagnosis of infective endocarditis. International Journal of Cardiology, 2016, 202, 564-570.	1.7	27
45	Automatic extraction of forward stroke volume using dynamic PET/CT: a dual-tracer and dual-scanner validation in patients with heart valve disease. EJNMMI Physics, 2015, 2, 25.	2.7	18
46	A protocol for a randomised, double-blind, placebo-controlled study of the effect of Uraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq0	0 0 r g₿ T /O	verbock 10 Tf
47	Partial oral treatment of endocarditis. American Heart Journal, 2013, 165, 116-122.	2.7	37
48	Failing Heart of Patients With Type 2 Diabetes Mellitus Can Adapt to Extreme Short-term Increases in Circulating Lipids and Does Not Display Features of Acute Myocardial Lipotoxicity. Circulation: Heart Failure, 2013, 6, 845-852.	3.9	20
49	Patient adherence to evidenceâ€based pharmacotherapy in systolic heart failure and the transition of followâ€up from specialized heart failure outpatient clinics to primary care. European Journal of Heart Failure, 2013, 15, 671-678.	7.1	37
50	Effect of Acute Hyperglycemia on Left Ventricular Contractile Function in Diabetic Patients with and without Heart Failure: Two Randomized Cross-Over Studies. PLoS ONE, 2013, 8, e53247.	2.5	17
51	Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. European Journal of Heart Failure, 2011, 13, 968-973.	7.1	63
52	Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1096-H1102.	3.2	141
53	Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1220-H1225.	3.2	34
54	Short-term changes in circulating insulin and free fatty acids affect Nt-pro-BNP levels in heart failure patients. International Journal of Cardiology, 2010, 144, 140-142.	1.7	15

HENRIK WIGGERS

#	Article	IF	CITATIONS
55	Proteomic analysis identifies mitochondrial metabolic enzymes as major discriminators between different stages of the failing human myocardium. Acta Cardiologica, 2009, 64, 511-522.	0.9	12
56	Letter by Wiggers et al Regarding Article by Tuunanen et al, "Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure― Circulation, 2007, 115, e545; author reply e547.	1.6	1
57	Selection of heart failure patients for cardiac resynchronisation therapy: a role for PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 307-308.	6.4	1
58	Adaptation of Nonrevascularized Human Hibernating and Chronically Stunned Myocardium to Long-Term Chronic Myocardial Ischemia. American Journal of Cardiology, 2006, 98, 1574-1580.	1.6	11
59	Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H938-H946.	3.2	20
60	Letter Regarding Article by Thijssen et al, "Temporal and Spatial Variations in Structural Protein Expression During the Progression From Stunned to Hibernating Myocardium― Circulation, 2005, 111, e378-9; author reply e378-9.	1.6	0
61	Suppressed phospholamban levels differentiate irreversibly dysfunctional from hibernating myocardium in humans. Scandinavian Cardiovascular Journal, 2005, 39, 55-59.	1.2	1
62	Electromechanical mapping versus positron emission tomography and single photon emission computed tomography for the detection of myocardial viability in patients with ischemic cardiomyopathy. Journal of the American College of Cardiology, 2003, 41, 843-848.	2.8	38
63	Coronary Artery Bypass Surgery in Heart Failure Patients with Chronic Reversible and Irreversible Myocardial Dysfunction: Effect on Heart Rate Variability. Cardiology, 2002, 98, 181-185.	1.4	3
64	Impact of daily life myocardial ischemia in patients with chronic reversible and irreversible myocardial dysfunction. American Journal of Cardiology, 2002, 89, 22-28.	1.6	6
65	Energy stores and metabolites in chronic reversibly and irreversibly dysfunctional myocardium in humans. Journal of the American College of Cardiology, 2001, 37, 100-108.	2.8	29
66	Prediction of Reversible Myocardial Dysfunction by Positron Emission Tomography, Low-Dose Dobutamine Echocardiography, Resting ECG, and Exercise Testing. Cardiology, 2001, 96, 32-37.	1.4	10
67	Electromechanical Mapping for Detection of Myocardial Viability in Patients With Ischemic Cardiomyopathy. Circulation, 2001, 103, 1631-1637.	1.6	74
68	Positron emission tomography and low-dose dobutamine echocardiography in the prediction of postrevascularization improvement in left ventricular function and exercise parameters. American Heart Journal, 2000, 140, 928-936.	2.7	17
69	Increased Amounts of Collagenase and Gelatinase in Porcine Myocardium Following Ischemia and Reperfusion. Journal of Molecular and Cellular Cardiology, 1998, 30, 1431-1442.	1.9	94
70	Chronic Total Occlusions of Coronary Arteries-Medical versus Surgical Treatment. Scandinavian Cardiovascular Journal, 1997, 31, 297-303.	1.2	6
71	Ischemia and Reperfusion of the Porcine Myocardium: Effect on Collagen. Journal of Molecular and Cellular Cardiology, 1997, 29, 289-299.	1.9	21